AbbVie Company Profile (NYSE:ABBV)

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie announced a quarterly dividend on Friday, June 23rd. Shareholders of record on Friday, July 14th will be paid a dividend of $0.64 per share on Tuesday, August 15th. This represents a $2.56 annualized dividend and a yield of 3.52%. The ex-dividend date is Wednesday, July 12th. View AbbVie's Dividend History.

AbbVie declared that its Board of Directors has initiated a share repurchase program on Sunday, April 9th 2017, which permits the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase up to 5% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's board of directors believes its shares are undervalued.

AbbVie Inc. (NYSE:ABBV) released its quarterly earnings results on Thursday, April, 27th. The company reported $1.28 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.26 by $0.02. The business had revenue of $6.54 billion for the quarter, compared to analysts' expectations of $6.49 billion. AbbVie had a return on equity of 148.83% and a net margin of 24.07%. The business's quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.15 earnings per share. View AbbVie's Earnings History.

AbbVie is scheduled to release their next quarterly earnings announcement on Thursday, July, 27th 2017. View Earnings Estimates for AbbVie.

AbbVie updated its FY17 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of $5.44-5.54 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.49.

13 equities research analysts have issued 12 month price objectives for AbbVie's stock. Their predictions range from $60.00 to $90.00. On average, they expect AbbVie's share price to reach $73.42 in the next year. View Analyst Ratings for AbbVie.

Here are some recent quotes from research analysts about AbbVie stock:

• 1. Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)
• 2. According to Zacks Investment Research, "AbbVie’s key drug Humira has been performing well and sales should continue to be driven by growing awareness, favorable clinical data, additional indications and expansion into new markets. Moreover, products like Viekira and Imbruvica have diversified AbbVie’s revenue base. Imbruvica has multi-billion dollar potential and AbbVie is exploring the potential to expand Imbruvica’s label into solid tumors and autoimmune diseases. AbbVie has a deep and promising pipeline and is also working on expanding its portfolio though additional deals. However, Viekira is facing intense pricing pressure and competition in the HCV market. Additionally, quite a few companies are working on bringing Humira biosimilars to market. Amgen’s biosimilar version of Humira received FDA approval in Sep 2016. Abbvie could see some of its dominant share in the arthritis market contract when Amgen’s new drug is launched." (9/28/2016)
• 3. Argus analysts commented, "strong" second quarter earnings print.The analysts noted that not only were AbbVie's results driven by sales of Humira and Imbruvica, but its pipeline also "strengthened" following the acquisition of Stemcentrix and a partnership with Boehringer Ingelheim for the commercial rights of a new immunology drug that is in a late stage trial.The analysts also stated that the earnings print confirmed Imbruvica's "rapid acceptance" which bodes well for future sales. Coupled with the Venclexta drug, AbbVie boasts two "powerful drugs" to treat first- and second-line CLL and other hematogical malignancies.Related Link: Investors Cheer AbbVie's Q2 Numbers, ForecastThe analysts also stated that AbbVie's stock is "attractively valued" at just 11.2x their 2017 earnings per share estimate, which is "well below" the average multiple of 14.5 of other companies under Argus' coverage.Finally, the analysts boosted their full-year 2016 adjusted earnings per share estimate to $4.84 from $4.80 and their 2017 earnings per share estimate to $5.95 from $5.90."The company has strengthened its product portfolio and pipeline through several deals over the past 12 months, and continues to post strong sales of Humira, aided by new indications," (8/8/2016)

AbbVie saw a decrease in short interest in the month of May. As of May 15th, there was short interest totalling 30,327,253 shares, a decrease of 7.1% from the April 28th total of 32,651,310 shares. Based on an average daily volume of 5,390,470 shares, the short-interest ratio is currently 5.6 days. Approximately 1.9% of the company's stock are sold short.

Some companies that are related to AbbVie include ConvaTec Group PLC (CTEC), Mallinckrodt PLC (MNK), Indivior PLC (INDV), Supernus Pharmaceuticals (SUPN), Advanced Accelerator Applications S.A. (AAAP), Repligen Corporation (RGEN), Eagle Pharmaceuticals (EGRX), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Aimmune Therapeutics (AIMT), Rockwell Medical (RMTI), Assembly Biosciences (ASMB), Novan (NOVN), Check-Cap (CHEK), CorMedix (CRMD), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).

AbbVie's management team includes the folowing people:

• Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer
• William J. Chase, Executive Vice President, Chief Financial Officer
• Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer
• Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary
• Carlos Alban, Executive Vice President - Commercial Operations
• Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer
• Timothy J. Richmond, Senior Vice President - Human Resources
• Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations
• Robert A. Michael, Vice President, Controller
• Robert J. Alpern M.D., Independent Director

AbbVie's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), BlackRock Inc. (0.00%), State Street Corp (4.58%), Bank of New York Mellon Corp (1.14%), Morgan Stanley (0.00%) and State Farm Mutual Automobile Insurance Co. (0.00%). Company insiders that own AbbVie stock include Carlos Alban, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

AbbVie's stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Glenview Capital Management LLC, Bank of New York Mellon Corp, APG Asset Management N.V., Miller Howard Investments Inc. NY, Parametric Portfolio Associates LLC, Fayez Sarofim & Co and Atalanta Sosnoff Capital LLC. Company insiders that have sold AbbVie stock in the last year include Carlos Alban, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

AbbVie's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Vanguard Group Inc., Renaissance Technologies LLC, State Street Corp, Prudential Financial Inc., Swiss National Bank and Atlantic Trust Group LLC. View Insider Buying and Selling for AbbVie.

Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AbbVie stock can currently be purchased for approximately $72.74.